An Indian drugmaker, Riemann Labs, has been found to have violated manufacturing and laboratory practices, according to a government health official who spoke to Reuters on Wednesday.

This comes after the cough syrup produced by the company was linked to the deaths of children in Cameroon. In response to concerns about Indian-made cough syrups being associated with child fatalities abroad, authorities have increased scrutiny of drug manufacturers.

Riemann Labs is the fourth Indian cough syrup maker to suspend production due to regulatory findings of lapses. The company did not provide any comments to Reuters, and one of its directors, Rajesh Bhatia, stated that he was not aware of the matter.

Regulators conducted inspections at Riemann Labs' production unit in Madhya Pradesh and issued a notice after discovering the violations in good manufacturing practices and good laboratory practices, although the specific nature of the violations was not specified.

Following the discovery of violations in manufacturing and laboratory practices at Riemann Labs, samples of all the company's products have been sent for testing. The appropriate actions will be determined based on the test results, according to Sudam Khade, the state's drugs controller.

The government directed Riemann Labs to halt manufacturing after inspections conducted by federal and state regulators.

The company has been identified as the maker of Naturcold cough syrup, which was linked to the deaths of at least six children in Cameroon, as reported by authorities there. Some media sources, however, have cited the deaths of 12 children in connection with the same batch of cough syrup.